Breathe Well Live Well
|
Hayes, Inc. Releases New Report on Bronchial Thermoplasty for Treatment of Asthma
Benzinga Hayes, Inc., a leading provider of unbiased health technology assessments and consulting services, recently released a health technology assessment on bronchial thermoplasty for the treatment of asthma. Since bronchial thermoplasty is a novel approach … |
View full post on asthma – Google News
|
Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at …
Benzinga Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed … |
View full post on asthma – Google News
|
Asthma and Allergy Foundation Announces Sponsorship of Institute of Medicine …
Benzinga To address these gaps in knowledge, research and data, the Asthma and Allergy Foundation of America (AAFA) announces its co-sponsorship of a new Institute of Medicine (IOM) consensus study on food allergy. The study, "Food Allergies: Global Burden, … |
View full post on asthma – Google News
|
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in …
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with … |
View full post on asthma – Google News
|
Relvar Ellipta Approved in Japan for Treatment of Asthma
Benzinga GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma (in cases where … GSK, Theravance Announce Relvar Ellipta Approval In Japan For Asthma … Double asthma approval in Japan lifts SkyePharma Asthma drugs head Japan approvals |
View full post on asthma – Google News
|
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Benzinga Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to … |
View full post on asthma – Google News
|
Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
Benzinga Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under … |
View full post on asthma – Google News
|
Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical …
Benzinga … the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma, … |
View full post on asthma – Google News
|
New Air Purifier Site Offers Asthma and Allergy Relief
Benzinga AirPurifierPro.com has a wide selection of air purifiers, including odor air purifiers, asthma air purifiers, allergy air purifiers and smoke air purifiers. Air purifier filters and cartridges are also available for purchase. … |
View full post on asthma – Google News
|
Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will …
Benzinga The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to … |
View full post on asthma – Google News